Structure-guided evolution of antigenically distinct adeno-associated virus variants for immune evasion
Open accessThe DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.
Abstract
Significance: Preexisting neutralizing antibodies (NAbs) against adeno-associated viruses (AAVs) pose a major, unresolved challenge that restricts patient enrollment in gene therapy clinical trials using recombinant AAV vectors. To tackle this problem, we developed a structure-guided approach to evolve AAV variants with altered antigenic footprints that cannot be recognized by preexisting antibodies. These proof-of-principle studies demonstrate that synthetic AAV variants can be evolved to evade neutralizing sera from different species—mice, nonhuman primates, and humans—without compromising yield and transduction efficiency or altering tropism. Our approach provides a roadmap for engineering any AAV strain to evade NAbs in prospective patients for human gene therapy.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Modifications in the NAb recognition sites can enhance transduction efficiency [190–193].”
From Immunogenicity of Recombinant Adeno-Associated Virus (AAV) Vectors for Gene Transfer (2023) · cites this paper as [191]
In the citing paper
“Capsid engineering for capsids with resistance to antibodies can be performed through rational design (82 -88).”
From A versatile toolkit for overcoming AAV immunity (2022) · cites this paper as [88]
In the citing paper
“based on understanding of the epitope responsible for antibody binding, mutations and insertions were introduced to disrupt antibody binding and thus generate novel capsids with reduced antibody af fi nity (82, 87 -89).”
From A versatile toolkit for overcoming AAV immunity (2022) · cites this paper as [88]
In the citing paper
“A novel capsid CAM130 had reduced NAb af fi nity against AAV1, but maintained comparable titer, transduction ef fi ciency, and tissue tropism (88).”
From A versatile toolkit for overcoming AAV immunity (2022) · cites this paper as [88]
In the citing paper
“Variants developed based on this analysis required 2-to 16-fold higher antibodies for neutralization compared to their parental serotype [89].”
From Immune responses to gene editing by viral and non-viral delivery vectors used in retinal gene therapy (2022) · cites this paper as [89]
Citations
Cites
Adenovirus-Associated Defective Virus Particles
Atchison, R. W., Casto, B. C., & Hammon, W. M. (1965) · Science · doi:10.1126/science.149.3685.754 · Cited by 1,004 · cited 1×
“, rhesus macaques) to harbor antibodies against AAV1 capsids (19).”
BackgroundEngineering adeno-associated viruses for clinical gene therapy
Kotterman, M. A., & Schaffer, D. V. (2014) · Nature Reviews Genetics · doi:10.1038/nrg3742 · Cited by 761
A viral assembly factor promotes AAV2 capsid formation in the nucleolus
Sonntag, F., Schmidt, K., & Kleinschmidt, J. A. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1001673107 · Cited by 392 · cited 1×
“The present study was designed to avoid manipulation of these residues owing to their involvement with SA binding and partial overlap with the region encoding the assembly-activating protein in the WT AAV genome (24).”
MethodWu, Z., Miller, E., Agbandje-McKenna, M., & Samulski, R. J. (2006) · Journal of Virology · doi:10.1128/jvi.00895-06 · Cited by 328 · cited 1×
“Specifically, AAV1 requires sialylated glycans for cell surface attachment, which in turn determines transduction efficiency (23).”
BackgroundSelf-citationIn Silico Reconstruction of the Viral Evolutionary Lineage Yields a Potent Gene Therapy Vector
Zinn, E., Pacouret, S., Khaychuk, V., Turunen, H. T., Carvalho, L. S., Andres-Mateos, E., Shah, S., Shelke, R., Maurer, A. C., Plovie, E., et al. (2015) · Cell Reports · doi:10.1016/j.celrep.2015.07.019 · Cited by 310
Hastie, E., & Samulski, R. J. (2015) · Human Gene Therapy · doi:10.1089/hum.2015.025 · Cited by 280 · cited 1×
“Since the approval of the first AAV1-based gene therapy in 2012, encouraging results from clinical trials involving AAV vectors for gene therapy for Leber congenital amaurosis (1), hemophilia (2), and other diseases have been reported (3).”
ResultMonteilhet, V., Saheb, S., Boutin, S., Leborgne, C., Veron, P., Montus, M.-F., Moullier, P., Benveniste, O., & Masurier, C. (2011) · Molecular Therapy · doi:10.1038/mt.2011.108 · Cited by 206
Chicoine, L., Montgomery, C., Bremer, W., Shontz, K., Griffin, D., Heller, K., Lewis, S., Malik, V, Grose, W., Shilling, C., et al. (2014) · Molecular Therapy · doi:10.1038/mt.2013.244 · Cited by 167 · cited 1×
“Studies also have demonstrated that several rounds of plasmapheresis can lower NAb titers from high to medium levels (as low as 1:20) in patients (26, 27); however, this approach does not appear to be as effective in further reducing medium-to-low NAb titers that preclude patient enrollment (27).”
BackgroundB-cell depletion is protective against anti-AAV capsid immune response: a human subject case study
Corti, M., Elder, M., Falk, D., Lawson, L., Smith, B., Nayak, S., Conlon, T., Clément, N., Erger, K., Lavassani, E., et al. (2014) · Molecular Therapy - Methods & Clinical Development · doi:10.1038/mtm.2014.33 · Cited by 140 · cited 1×
“One promising approach involves the use of immunosuppressive agents that can mitigate NAb generation after vector dosing (25).”
BackgroundInterpretation of electron density with stereographic roadmap projections
Xiao, C., & Rossmann, M. G. (2006) · Journal of Structural Biology · doi:10.1016/j.jsb.2006.10.013 · Cited by 140 · cited 2×
“For the present study, antigenic footprints for three distinct mAbs (4E4, 5H7, and ADK1a) were visualized on the AAV1 capsid (Protein Data Bank ID code 3NG9), and roadmap images were generated using RIVEM (29).”
BackgroundMethodTseng, Y.-S., & Agbandje-McKenna, M. (2014) · Frontiers in Immunology · doi:10.3389/fimmu.2014.00009 · Cited by 134 · cited 22×
“It is important to note that the different capsid antigenic motifs (CAMs) listed above are subsets of VRs IV, V, and VIII (8).”
BackgroundMethodSelf-citationCapsid antibodies to different adeno-associated virus serotypes bind common regions
Gurda, B. L., DiMattia, M. A., Miller, E. B., Bennett, A., McKenna, R., Weichert, W. S., Nelson, C. D., Chen, W.-J., Muzyczka, N., Olson, N. H., et al. (2013) · Journal of Virology · doi:10.1128/jvi.00622-13 · Cited by 127 · cited 3×
“Here we tested this hypothesis using AAV1 as a template, which we chose because of the availability of extensive structural information pertaining to this capsid complexed with different mAbs and its cognate glycan receptor, sialic acid (SA) (9, 10, 16).”
BackgroundMethodSelf-citationGreenberg, B., Butler, J., Felker, G. M., Ponikowski, P., Voors, A. A., Pogoda, J. M., Provost, R., Guerrero, J., Hajjar, R. J., & Zsebo, K. M. (2016) · Gene Therapy · doi:10.1038/gt.2015.109 · Cited by 111 · cited 1×
“Furthermore, most patients with high NAb titers against AAV serotype 2 also have measurable titers to AAV1, suggesting cross-reactivity between serotypes (4).”
BackgroundAAV: An Overview of Unanswered Questions
Berns, K. I., & Muzyczka, N. (2017) · Human Gene Therapy · doi:10.1089/hum.2017.048 · Cited by 111 · cited 1×
“Thus, the presence of preexisting anti-AAV NAbs remains a major unaddressed challenge for gene therapy (7).”
BackgroundCharacterization of the Adeno-Associated Virus 1 and 6 Sialic Acid Binding Site
Huang, L.-Y., Patel, A., Ng, R., Miller, E. B., Halder, S., McKenna, R., Asokan, A., & Agbandje-McKenna, M. (2016) · Journal of Virology · doi:10.1128/jvi.00161-16 · Cited by 101 · cited 2×
“Here we tested this hypothesis using AAV1 as a template, which we chose because of the availability of extensive structural information pertaining to this capsid complexed with different mAbs and its cognate glycan receptor, sialic acid (SA) (9, 10, 16).”
BackgroundMethodSelf-citationMapping a Neutralizing Epitope onto the Capsid of Adeno-Associated Virus Serotype 8
Gurda, B. L., Raupp, C., Popa-Wagner, R., Naumer, M., Olson, N. H., Ng, R., McKenna, R., Baker, T. S., Kleinschmidt, J. A., & Agbandje-McKenna, M. (2012) · Journal of Virology · doi:10.1128/jvi.00218-12 · Cited by 93
Self-citationWikoff, W. R., Wang, G., Parrish, C. R., Cheng, R. H., Strassheim, M. L., Baker, T. S., & Rossmann, M. G. (1994) · Structure · doi:10.1016/s0969-2126(00)00062-9 · Cited by 88
Structure of adeno-associated virus-2 in complex with neutralizing monoclonal antibody A20
McCraw, D. M., O’Donnell, J. K., Taylor, K. A., Stagg, S. M., & Chapman, M. S. (2012) · Virology · doi:10.1016/j.virol.2012.05.004 · Cited by 84
AAV Ancestral Reconstruction Library Enables Selection of Broadly Infectious Viral Variants
Santiago-Ortiz, J., Ojala, D. S., Westesson, O., Weinstein, J. R., Wong, S. Y., Steinsapir, A., Kumar, S., Holmes, I., & Schaffer, D. V. (2015) · Gene Therapy · doi:10.1038/gt.2015.74 · Cited by 83
Structural Comparison of Different Antibodies Interacting with Parvovirus Capsids
Hafenstein, S., Bowman, V. D., Sun, T., Nelson, C. D. S., Palermo, L. M., Chipman, P. R., Battisti, A. J., Parrish, C. R., & Rossmann, M. G. (2009) · Journal of Virology · doi:10.1128/jvi.02532-08 · Cited by 81
Development of AAV serotype-specific ELISAs using novel monoclonal antibodies
Kuck, D., Kern, A., & Kleinschmidt, J. A. (2007) · Journal of Virological Methods · doi:10.1016/j.jviromet.2006.10.005 · Cited by 74 · cited 1×
“The three mAbs that we selected for these studies were generated from mice immunized with AAV1 (6, 17).”
MethodMarsic, D., Govindasamy, L., Currlin, S., Markusic, D. M., Tseng, Y.-S., Herzog, R. W., Agbandje-McKenna, M., & Zolotukhin, S. (2014) · Molecular Therapy · doi:10.1038/mt.2014.139 · Cited by 72 · cited 1×
“This observation is consistent with findings reported in other AAV libraries (18), in which simultaneous mutagenesis of these epitopes on the same capsid reduced viral titers, presumably owing to assembly defects.”
ResultSelf-citationTseng, Y.-S., Gurda, B. L., Chipman, P., McKenna, R., Afione, S., Chiorini, J. A., Muzyczka, N., Olson, N. H., Baker, T. S., Kleinschmidt, J., et al. (2015) · Journal of Virology · doi:10.1128/jvi.02710-14 · Cited by 70 · cited 7×
“We analyzed previously resolved, cryoreconstructed structures of AAV1 capsids complexed with four different Fabs of mouse anti-AAV1 mAbs (9, 10).”
BackgroundMethodSelf-citationCNS-restricted Transduction and CRISPR/Cas9-mediated Gene Deletion with an Engineered AAV Vector
Murlidharan, G., Sakamoto, K., Rao, L., Corriher, T., Wang, D., Gao, G., Sullivan, P., & Asokan, A. (2016) · Molecular Therapy - Nucleic Acids · doi:10.1038/mtna.2016.49 · Cited by 68 · cited 2×
“steps involving the harvesting of recombinant AAV vectors and downstream purification were carried out using updated methods (28).”
MethodSelf-citationStrategies to circumvent humoral immunity to adeno-associated viral vectors
Tse, L. V., Moller-Tank, S., & Asokan, A. (2015) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.2015.1035645 · Cited by 61 · cited 3×
“Although CAM variants can be reengineered further, if warranted, our structureguided approach complements other methods to circumvent preexisting humoral immunity in prospective patients that are currently being explored in preclinical studies (5).”
BackgroundSelf-citationHarbison, C. E., Weichert, W. S., Gurda, B. L., Chiorini, J. A., Agbandje-McKenna, M., & Parrish, C. R. (2012) · Journal of General Virology · doi:10.1099/vir.0.035113-0 · Cited by 54 · cited 3×
“An earlier study showed that 4E4 and 5H7 reduce AAV1 transduction by affecting both the binding and postattachment steps essential for host cell transduction (6).”
BackgroundMethodSelf-citationBloom, M. E., Best, S. M., Hayes, S. F., Wells, R. D., Wolfinbarger, J. B., McKENNA, R. V., & Agbandje‐McKenna, M. (2001) · Journal of Virology · doi:10.1128/jvi.75.22.11116-11127.2001 · Cited by 52
Self-citationPrediction of adeno-associated virus neutralizing antibody activity for clinical application
Wang, M., Crosby, A., Hastie, E., Samulski, J. J., McPhee, S., Joshua, G., Samulski, R. J., & Li, C. (2015) · Gene Therapy · doi:10.1038/gt.2015.69 · Cited by 45 · cited 1×
“Assay parameters were carefully controlled as outlined previously (30).”
BackgroundNienhuis, A. W., Nathwani, A. C., & Davidoff, A. M. (2016) · Human Gene Therapy · doi:10.1089/hum.2016.018 · Cited by 27
Success against blindness encourages gene therapy researchers
Ledford, H. K. (2015) · Nature · doi:10.1038/526487a · Cited by 10
Cited by
Adeno-associated virus vector as a platform for gene therapy delivery
Wang, D., Tai, P. W. L., & Gao, G. (2019) · Nature Reviews Drug Discovery · doi:10.1038/s41573-019-0012-9 · Cited by 2,444
Engineering adeno-associated virus vectors for gene therapy
Li, C., & Samulski, R. J. (2020) · Nature Reviews Genetics · doi:10.1038/s41576-019-0205-4 · Cited by 1,175
Adeno-associated virus as a delivery vector for gene therapy of human diseases
Wang, J.-H., Gessler, D. J., Zhan, W., Gallagher, T. L., & Gao, G. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01780-w · Cited by 904
“382 While these discoveries help guide capsid engineering toward escape from pre-existing immunity imposed by antibodies, 70 it is important to keep in mind that the rAAV is quite small relative to the antibody, such that a few antibodies binding to the virion is suf fi cient to cover the viral…”
BackgroundMethodEmerging issues in AAV-mediated in vivo gene therapy
Colella, P., Ronzitti, G., & Mingozzi, F. (2018) · Molecular Therapy - Methods & Clinical Development · doi:10.1016/j.omtm.2017.11.007 · Cited by 881
AAV Vector Immunogenicity in Humans: A Long Journey to Successful Gene Transfer
Costa Verdera, H., Kuranda, K., & Mingozzi, F. (2020) · Molecular Therapy · doi:10.1016/j.ymthe.2019.12.010 · Cited by 641
Metadata
- Authors
- Tse, L. V., Klinc, K. A., Madigan, V. J., Castellanos Rivera, R. M., Wells, L. F., Havlik, L. P., Smith, J. K., Agbandje-McKenna, M., & Asokan, A.
- Affiliations
- University of North Carolina at Chapel Hill (US)
- Gene Therapy Center, The University of North Carolina at Chapel Hill, Chapel Hill, NC 27599;
- University of Florida (US)
- Department of Biochemistry and Molecular Biology, University of Florida, Gainesville, FL 32611;
- Venue
- Proceedings of the National Academy of Sciences
- Publisher
- National Academy of Sciences
- Published
- 2017-05-30
- Volume
- 114
- Issue
- 24
- Pages
- E4812-E4821
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- PMC
- PMC5474820
- OpenAlex
- W2617246817
- Cited by
- 210
- References
- 30
- Citations by year
- 2026: 11 · 2025: 27 · 2024: 19 · 2023: 30 · 2022: 29 · 2021: 25 · 2020: 26 · 2019: 21 · 2018: 15 · 2017: 7
- FWCI
- 12.53
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Proceedings of the National Academy of Sciences (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- HHS | NIH | National Heart, Lung, and Blood Institute (R01HL089221, P01HL112761)
- HHS | NIH | National Institute of General Medical Sciences (R01GM082946, T32-GM008799)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
- Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
- Keywords
- adeno-associated virus, neutralizing antibodies, immune evasion, AAV1, gene therapy vectors, rhesus monkeys, transduction efficiency
- MeSH terms
- Dependovirus, Amino Acid Sequence, Animals, Antibodies, Viral, Antigen-Antibody Complex, Antigenic Variation, Antigens, Viral, Female, Genetic Vectors, Humans, Macaca mulatta, Mice, Inbred BALB C, Models, Molecular, Serotyping, Genetic Therapy, Directed Molecular Evolution, Capsid Proteins, Mice, Immune Evasion, Antibodies, Neutralizing, HEK293 Cells
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.